Valutazione economica di una vaccino bifrontale contro il virus respiratorio sinciziale prefusione F per la vaccinazione materna in Svezia: efficacia economica e impatto sul budget.

AIMS: To compare the clinical and economic outcomes of three infant RSV prevention strategies, monoclonal antibody prophylaxis with nirsevimab alone, maternal RSVpreF vaccination alone, and maternal RSVpreF vaccination with complementary nirsevimab versus no intervention in Sweden, to estimate cost-effectiveness and budget impact. METHODS: A population-based, multi-cohort Markov model followed 12 monthly birth cohorts from birth to 1 year with age- and season-specific RSV risks. Three seasonal (October-February) strategies (87% uptake) were evaluated versus no intervention: monoclonal antibody prophylaxis with nirsevimab alone; maternal RSVpreF vaccination alone; and maternal RSVpreF vaccin